Public commenter urges board to reject OptiMed specialty carve‑out over patient‑funding concerns

During the public comment period a community member urged the board to vote no on the proposed OptiMed specialty‑medication carve‑out, warning that so‑called alternative funding programs (AFPs) can produce denials, delays and higher long‑term costs for patients.

The speaker said AFPs may reclassify prescriptions as a carve‑out and force patients into third‑party programs that can siphon manufacturer assistance or other support, and argued that would harm employees and families. "AFPs are known to lead to denials, delays, and excessive costs for patients often through a set of convoluted moves," the commenter told trustees.

District benefits staff and the USI consultant addressed the concerns during the benefits presentation, saying the proposed OptiMed carve‑out is structured as an enhanced benefit and is not driven primarily by manufacturer assistance; the consultant said members obtaining covered specialty medications through OptiMed would pay $0 out‑of‑pocket through the program and that, in their view, OptiMed is accredited and performs domestic procurement. Board members pressed staff on whether participating members would be forced to change medications and on how out‑of‑pocket costs would be treated for deductible accounting; staff repeatedly said there is no intention to change current prescriptions and that any member out‑of‑pocket costs would count toward deductible and maximums consistent with plan rules.